ProfileJobs

GlycoMimetics

Healthbiotechdrug developmentoncologypharma

GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2003
Size (employees)
42 (est)+11%
Website
glycomimetics.com
GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Key People at GlycoMimetics

Brian Hahn

Brian Hahn

Chief Financial Officer
John Baldwin

John Baldwin

Director
Michael Henos

Michael Henos

Director
Franklin H. Top

Franklin H. Top

Director
William Gust

William Gust

Director
M. James Barrett

M. James Barrett

Chairman of the Board of Directors

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville
Rockville, US (HQ)
9708 Medical Center Dr

GlycoMimetics Data and Metrics

GlycoMimetics Financial Metrics

GlycoMimetics's revenue was reported to be $18.5 k in FY, 2016
USD

Net income (Q1, 2017)

(7.9 m)

Market capitalization (25-Jul-2017)

247.8 m

Cash (31-Mar-2017)

34.6 m
GlycoMimetics's current market capitalization is $247.8 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

15 m20.1 m18.5 k

Revenue growth, %

34%(100%)

Operating expense total

26.2 m32.9 m

EBIT

(11.1 m)(12.8 m)

EBIT margin, %

(74%)(64%)

Net Income

(11.1 m)(12.8 m)(31.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)
USDFY, 2014FY, 2015FY, 2016

Cash

55.2 m46.8 m40 m

Accounts Receivable

13.6 m

Inventories

916.2 k441.8 k478.5 k

Current Assets

56.1 m47.2 m40.5 m

PP&E

452.3 k521.4 k1.1 m

Total Assets

57.3 m48.5 m42.4 m

Accounts Payable

874 k564.2 k1.6 m

Current Liabilities

6.5 m7.7 m6.3 m

Total Liabilities

7.1 m

Additional Paid-in Capital

125.2 m127.6 m154.3 m

Retained Earnings

(74.4 m)(87.2 m)(119 m)

Total Equity

50.8 m40.5 m35.3 m

Financial Leverage

1.1 x1.2 x1.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

66.2 m61.4 m46.6 m40.2 m53.8 m38.8 m53.1 m45.3 m34.6 m

Accounts Receivable

20 m

Current Assets

67.1 m61.9 m47.3 m60.8 m54.5 m39.5 m54.5 m46.5 m35.3 m

PP&E

420.6 k481.9 k420.4 k579.2 k567.2 k491.4 k488 k676.6 k1.1 m

Total Assets

67.5 m62.4 m48.5 m62 m55.7 m40.7 m55.8 m48 m37.2 m

Accounts Payable

472.2 k583.7 k1.2 m1.1 m633.1 k1.6 m1.4 m1.2 m511.7 k

Current Liabilities

3.6 m4.7 m4.1 m6.8 m6.9 m5.7 m6.1 m5.4 m4.5 m

Additional Paid-in Capital

124.3 m124.7 m125.8 m126.3 m127 m129.5 m151.6 m152.4 m158.8 m

Retained Earnings

(60.4 m)(67 m)(81.5 m)(71.1 m)(78.3 m)(94.7 m)(102.8 m)(110.6 m)(126.9 m)

Total Equity

63.9 m57.7 m44.4 m55.2 m48.7 m34.8 m48.9 m41.8 m31.9 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.1 x1.1 x1.2 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(11.1 m)(12.8 m)(31.8 m)

Depreciation and Amortization

158.7 k191.5 k190.5 k

Accounts Receivable

(1.9 m)(1.7 m)(1.9 m)

Inventories

1.7 m474.4 k(36.7 k)

Accounts Payable

(270.9 k)(309.8 k)1 m

Cash From Operating Activities

52.9 m(8.4 m)(29.7 m)

Purchases of PP&E

(212.6 k)(268.6 k)(704.2 k)

Cash From Investing Activities

(212.6 k)(268.6 k)(704.2 k)

Cash From Financing Activities

57.4 m114.1 k23.7 m

Income Taxes Paid

80 k80 k80 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

2.9 m(3.7 m)(7.1 m)3.3 m(3.9 m)(7.6 m)(15.6 m)(23.5 m)(7.9 m)

Depreciation and Amortization

73.5 k114.3 k44.2 k90.5 k142.4 k47.2 k93.9 k139.7 k54.3 k

Accounts Receivable

(20 m)

Accounts Payable

(672.7 k)(561.2 k)299.5 k222.5 k(240.9 k)1 m816.9 k682.5 k(1.1 m)

Cash From Operating Activities

6.6 m1.9 m(8.7 m)(14.8 m)(1.3 m)(9.2 m)(16.3 m)(23.8 m)(9.1 m)

Purchases of PP&E

(95.7 k)(197.7 k)(2.3 k)(207 k)(265.4 k)(17.3 k)(40.3 k)(265.6 k)(63 k)

Cash From Investing Activities

(95.7 k)(197.7 k)(2.3 k)(207 k)(265.4 k)(17.3 k)(40.3 k)(265.6 k)(63 k)

Cash From Financing Activities

57.4 m57.4 m75.4 k90.5 k110.7 k1.3 m22.6 m22.5 m3.7 m
Y, 2017

Financial Leverage

1.2 x

GlycoMimetics Market Value History

Market Position of GlycoMimetics

Competitors

Galectin Therapeutics
Health - Public
MEI Pharma
Health - Public
Moleculin Biotech
Health - Public
Affigen
Health - Private
Compare competitors

GlycoMimetics Company Life and Culture

You may also be interested in